CurePSP program recruits patients for AbbVie, BMS trials

Non-profit CurePSP (Timonium, Md.) said it formed the Patient Engagement Program to assist in patient recruitment for clinical trials to treat degenerative brain diseases including progressive supranuclear palsy (PSP).

CurePSP said it agreed with AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb Co. (NYSE:BMY) to recruit patients for Phase I studies of therapies to treat PSP. In July, AbbVie and C2N Diagnostics LLC (St. Louis, Mo.) began a Phase I study of C2N-8E12, a recombinant humanized antibody targeting microtubule-associated protein tau (tau; MAPT; FTDP-17) in neurofibrillary tangles in the brain. Last month, BMS started a Phase I study of BMS-986168 ( IPN007), a humanized mAb targeting tau. Both compounds have Orphan Drug designation from FDA. ...